Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Medicover, Audiocast, Q3'24

By Inderes10/30/2024, 8:30 AM
Medicover

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Fredrik Rågmark
00:01 - 17:27

Good morning, everyone. Nice of you to join us for our Q3 results presentation. Before I start going into the presentation, I would just like to mention that this is the last quarter with Joe Ryan as CFO, who will be taking us through the results today. I will be coming back to Joe at the end of the presentation today. And also we have in the room with us here, Anand Patel, who you have seen. We have recruited him as the successor to Joe, who sits in on the presentation today, although he will not be speaking. But just so you are all aware, both of them are in the room. The third quarter overall message is that it was a very good quarter, actually very strong. And robust delivery. We continue the very strong and visible trend we have reported throughout the first half of the year, with strong and even increasing organic revenue growth, coupled with expanding margins in both divisions, as we will go through in detail. And in addition to that, very strong operating cash flow. So I think those are the sort of three cornerstones we had. Organic revenue, which ticked up above 17% to 17.4%, which obviously speaks for itself, represented by both divisions. Really. We will come back to that in more detail. Operating cash flow. I also added this in here for your information; you'll find that in some of the details of the quarterly reporting. I think it's interesting to see if we look at the rolling 12-month figure for our net operating cash flow, which is 240.2 million here in the third quarter. That's up 18% versus the same period last year. But perhaps more importantly, it is the strongest quarter ever from that operating cash flow measure on a rolling 12-month basis. We've had since we listed the company. And that includes, you know, these rather exceptional COVID-19 years. So that's a really, I think, a very good illustration of the progress we are making, because obviously cash flow is generally the best measure to assess performance. I think, again, Healthcare Services continue to show very strong organic growth. You might almost get used to it, but nevertheless, there is very strong underlying operational organic growth that drives profitability improvement. And that's really coming across the board. We've discussed the importance of utilizing the infrastructure we have invested in each quarter for quite some time now. And of course, that's particularly true in Healthcare Services with the investments, particularly in India and Romania. And we will talk more about that. But most importantly, it's very visible in the numbers we report. Likewise, Diagnostic Services are growing very nicely. You know, we continue the trend. We have seen the first half of the year with solid double-digit organic growth again. And even on a volume basis for Diagnostic Services, less price on that side because half of it is in Germany. But nevertheless, a very strong position. We are also recording an impairment charge of 16.4 million on our Nordic fertility businesses in Denmark and Norway, as well as the German dental activities. And we will talk about those details later on in the presentation. So, going to the second page that you recognize. So overall then, just short of 20% growth, 19.8% to be exact, 17.4% organic acquired revenue, almost non-existent. You know that we have been very inactive now for some, uh, well, nine, well, seven quarters really, on the inorganic front. Um, so that's very visible in that number. Good growth in fee for service. Of course, given the overall impact of fee-for-service in our revenue base. And I have already made the point, I think significantly, on the operating cash flow, on the pie charts. Just pointing out, I think it's worthwhile. You see Poland, uh, if you had the Q3 2024 pie chart in front of you. Poland was then 48%. So despite us growing quite nicely in many other geographies, Poland is growing so strongly. So, its share has popped up to 50%. So you see that 25% growth out of Poland, obviously rather exceptional. I'm sure, as Joe will comment on later on, there is some foreign exchange support in that number, clearly on the back of the zloty strengthening. But also the underlying real number is very significant. You see Germany again; worthwhile to point out, up 15%. And that is despite a pricing situation that is a constant topic of discussion. Germany performed very strongly. Uh, Romania, you see on the back, of course, largely of additional hospital capacity that we put into healthcare services in Romania and India. You see there 10%. I talk about 11% when we discuss our hospital business. So the fact that India, as a geography, is at 10% is due to the fertility businesses that we've exited, which we have talked about before. So more importantly, the hospital business in Europe is up 11% in local currency, up 13%. Then if you go to the next slide, looking at the profitability, two points to make: you remember last time around the third quarter last year, we had an exceptional personnel credit that we allocated to central administrative costs, not to impact the trading margins in the two divisions. That was, you know, these sort of contingent acquisition payments that would not be paid. So, we had to credit that back to the P&L now. So that's why you see actually shrinking margins on the reported number for all intents and purposes. When we look at how the business is doing, I think we need to take that out because it was one of non-cash, non-operational. And in doing so, as you see here in the slightly smaller print, we have a good, healthy margin increase on all results measures and very much in line with what you have seen during quarter one and quarter two so far this year, and likewise what we expect to see going forward. Joe will speak more about the goodwill impairment. But of course, that then goes to operating profit and to net profit, which is then significantly impacted, as I noted in my CEO statement. And also, just for full transparency, if we neutralize the impairment charge, in addition to the 4 million, our operating profit EBIT is up just short of 60% versus the prior year quarter. And a good evidence of operational leverage. A point that we have made, I think, every quarter recently, is the fact that despite having quite significant margin expansion, we still carry a significant drag from the larger hospitals that we have opened. Specifically, as noted in this report, over the past two years or so, since the third quarter of 2022, we have opened six large units, five of them in India and one in Bucharest; two of these six have just been opened. And during the third quarter this year. So during July and August of 2024, two of those six turned positive during the quarter. And that's a really important message because, of course, as they turn positive, they no longer lose money. And now as a group, those six hospitals contributed almost -5 million on an EBITDA basis in this quarter. So for the overall group, that's close to 90 basis points of additional margin just by bringing them to zero, let alone, of course, getting to the profitability levels where we want and need them to be. So that is really, you know, the single largest item that keeps improving our margins on a reported basis as we progress. Then turning to healthcare services again, very impressive growth. Organic growth above 18%. So 18.3%. That splits pretty evenly, 50-50, into price and volume. So nine percentage points of price and slightly more than nine percentage points of volume growth, with almost non-existent acquired revenue. And you see fee-for-service up 16%, just above half of the divisional revenue. And I think we can say universally there is a very strong demand picture across the line here. I spoke before about Poland. Romania is certainly in a similar situation, as well as India. As I mentioned earlier, India experienced a 13% increase in local currency. A good member intake in our corporate paid business. So overall, a very solid picture for revenue-wise healthcare services. That is then transforming into, you know, good, robust profit improvement, 20 basis points up on EBITDA, 70 basis points up on net operating cash flow. It is really visible in terms of the improvements we are making here. I made the point already in terms of the six hospital units. Now, if you look only at the healthcare services division and that amount of money, you see that's even 130 basis points additional EBITDA margin on top of the 9.8 that we report in this quarter. As a proportion of the overall reported margin right now, it is significantly high, as you can see. And two of the six have turned positive in the quarter. We just opened an additional two, which will obviously take some time to bring to positive territory. But it's really important that you understand the underlying dynamics in terms of what is driving the improvement. Then we have a slide which we have had for a couple of quarters just to show you where the Indian hospitals are and the maturity profile of them. And I will only point out on the map this time around, you see the slightly more light blue bulbs; you have Warangal up to the middle right, which opened during the summer, and you have Bangalore down in the new state of Karnataka, which also opened during the third quarter. So those are the two additions during the quarter. Then, moving on to Diagnostic Services, there was a good growth. Very solid growth, 15.5% up of which organic was 15.3% and then price representing four percentage points of that. So you see volume growth being 11% plus. And if you think about 4% price growth and that basically half of the business is in Germany, and healthcare services had 9% price growth, it's 8% on a like-for-like basis, which is more or less 8%. So quite similar between the two divisions when you compensate for the situation in Germany. So overall, good growth driven both by some price, obviously, but also by a good test mix development. Underlying good test growth. And you know, we have commented for a number of quarters on the situation in Germany, and you will probably have some questions about that. Uh, you recall us saying 2 or 3 quarters back that we expected price increases, but now we see prices being flat. We are working hard to address this situation and compensate in terms of cost structure. And we are confident in the work we do in that area. And I think it is relevant to make that comment that, of course, Germany, being half of the division and the significant margin growth that you see in Diagnostic Services, is largely driven by Germany, given that it's half of the division. And I think the fact that we are able to grow our margins in the division, largely out of Germany, despite the situation we've reported, with prices being stable and not growing, is a good illustration. So we are confident that we will manage that situation going forward. But I'm sure you will have some additional questions relating to that. So in terms of margins coming out of the ECS, we have said many times, you know, this is more of a marginal contribution type of business. So when we put more volume into the network, a larger proportion of that additional revenue will flow through as an additional contribution. And that's really evident when you look at the margin expansion. You know, you've seen that picture before, and that's a picture that we expect to continue. Obviously, it's a good picture to report. And just like the comment I made on healthcare services, it really is a good solid demand picture across our markets in Germany and the other countries; we don't have a bullet here on Ukraine. I shall mention Ukraine separately. You know, there is no change. You read the newspapers as much as we do, I'm sure. So there's really no change in the situation in the hostilities with Russia. Our business performs surprisingly well in Ukraine, I should say. The efforts being made by our team and our leadership in Ukraine are nothing less than heroic in managing that situation. We continue with what we call the NHS pilot, which entails conducting a substantial volume of tests with the local public system, anticipating reimbursement for those during 2025. That slightly impacts the test and sort of revenue mix out of DCS. It's well described in the report. I just want to mention that we are very supportive. We support Ukraine. But you know, there's no difference in outlook in terms of when that conflict will end. All right. So with that, I will hand over to Joe for the financial overview.

Joe Ryan
17:27 - 29:37

Thank you, Fredrik. So my preferred measure here is adjusted EBITDA. So, EBITDA after lease costs. That's more in line with our cash flows from our operating business, as the real estate we use in the business acts as a recurring structure of our capital, and a recurring cash outflow for the group, and that measure grew by 16%. So we're up to 48.5 million. Um, last time around 41.9 million. And the margin there is down. We're down from 9.2 to 9.5. So when you adjust for the €4 million credit we had exceptionally last time around, then that margin comes up and the growth comes up to 28%, and the margin comes in line to reflect what's happening in the underlying business. So we're up. Um, we're up 0.6 percentage points on that margin level. So it shows a good development in our cash flows. And you see that reflected later on in the cash flow numbers as well. Healthcare services weren't impacted by this one-off credit. The divisions, the segments of healthcare services, are 36.1 million and 28.5 million. Last time around. So you can see we've got a 0.4 percentage point increase in the margin there, and the flow-through on the incremental volumes and operational leverage. But the operational leverage is a bit obscured. We see that on some lines and very clearly, for instance on lease costs and some other items. But it's a bit clouded by the startup costs as well that we incur in relation to the new hospitals we have running on the diagnostic side, 19.5 versus 15.2. So you can see the absolute amounts there and the margin quite clearly: up 12% versus 10.7%. So it's a little bit clearer here in terms of the flow through of the contributions and the increased volumes coming from the fee-for-service markets. Operational leverage you can see is much clearer on the diagnostic side, where they have fewer new units diluting the figures, continuing to grow with room for growth here. I think we've got that coming. Um, as we, um. As we've explained previously, you can see that for many quarters now, we have noticed the maturing profile of the units that we currently operate. We've got the volume increments which will feed through in that. And on top of that, we have various different efficiency initiatives working as well to improve our efficiency and margins. As mentioned, we had an impairment charge this quarter, 16.4 million overall in two smaller business areas. We had Nordic IVF activities, and there was an impairment of 9.8 million. And, our German dental business unit incurred a 6.6 million impairment. And that's about one third of the goodwill that we carry for the Nordics and about half of the goodwill we carry for the German dental businesses. Um, these are relatively small units. We have always been conservative in terms of our goodwill carrying values. We still carry €515 million of goodwill after those impairment charges. At the end of the quarter and with regard to all other items in our goodwill, we have ample headroom, ensuring that there are no issues with any of the goodwill we are carrying. It is very well supported. So that means then there's a clean situation for when I hand over to the new CFO. So, it's like leaving a clean deck, so to speak. That's approximately 3% of our carrying goodwill value. It's worth noting that one of the drawbacks of writing that down is that it obviously impacts our net profits and earnings per share. So, if we adjusted for just this item, 16.4 million, that would be €0.109 higher in terms of the earnings per share. Unfortunately, I leave on a slightly negative note in terms of that. But at least it's definitely a clean slate going forward. If we look at our leverage levels, they have come down. So we come down to 3.1, versus 3.3, this is our basis of looking at leverage, where we look at our loans payable net of cash and liquid investments to adjusted EBITDA after leases. So we're not including lease liabilities in this measure. Now that's, sort of, like, we've deleveraged, but I think that what is hidden there is that the leverage has been much larger than that. So we've got €52 million of cash and debt recognition in terms of buying non-controlling interests. And that sort of doesn't change the profit measure in the leverage calculation. So, that's to increase our shareholders' share of profits and to feed through into EPS increase. We financed that and still reduced our leverage. Inorganic acquisitions. 18.1 this time last year was 16.4 for the nine months. Um, so in those units we've had a little bit of investment in Germany. We bought out a clinic, a lab in Berlin, and integrated that into our Berlin assets, and then also a nice addition with the genetics unit in the west of the country; we have some dental units as well. Within those figures, net debt overall increased by 62.8 million for the nine months. And our working capital side has been very benign, with a 12.4 million increase for the nine months as well. We have a very good working capital cycle, very benign in almost all of our units, as you can see, with the growth we've achieved with a very small net investment in working capital. Our effective tax rate comes in at. We keep that at 26%, projected for the year end through to the year end. Our operating cash flow is up by 25%. As I mentioned earlier, you can see that flow through in terms of the cash that we're generating. So, 25% up at 72.3 million. And if you look at the nine months, we're just short of 200 million versus just over 160 million last year. So that's up 22%. So we are generating more cash out of the businesses, as you would expect, in terms of investing and growing the activities. And then, if we look at our free recurring cash flow, what we've got left after our lease payments and after we reinvest in our maintenance side of the business, that was just short of €35 million, at €34.8 million. So up 35% for the quarter. And if we look at the nine months, that was just short of 90 million, up from 66 million, so that's 35% up. So really, good strong development for the nine months. If I look at that as a percentage of revenues, then we can see a very clear increase there. So we're at 5.8% from 5.1%. So we are not only generating absolute growth with the size of the business, but we're also increasing the margin in respect of that free cash flow, free recurring cash flow. We then reinvested in the business. So our growth investments amounted to just shy of 20 million for the quarter. And if I look at the nine months, we're at 55 million, up slightly on where we were in absolute amounts of money in the prior year. Of that 55 million, around about a third or just over a third has been invested in our Indian activities, particularly in our hospitals. So we've got three large hospital units in there that we've invested in, with them in Warangal, outside Hyderabad, and a beautiful facility in Bangalore. And then we've also got an oncology facility in Vizag, which features brand new state-of-the-art collection machines as well. So, really nice facility, and that's picked up really well. Then we have some Polish gyms, where we've spent quite a bit, particularly in terms of orienting them towards resilience, and in meeting new statutory obligations on our healthcare businesses, deemed as critical infrastructure. We're looking then at the next slide, you can see here in terms of that CapEx on the left-hand side you can see our free recurring cash flows. You can see that as a percentage increase that from 5.1 to 5.8%. And you can see then our organic growth investment with the darker column there, in terms of where we've reinvested part of those free cash flows and our organic CapEx, so this is CapEx excluding leases. So, real assets, if you like, you can see there in terms of the graphs, 5.4% for the quarter, as a percentage of revenues, and 5.3% as a percentage of revenues for the nine months. So we are up in terms of the absolute amounts. But you can see we are, for the nine months we are down in terms of a percentage, you will see a slightly higher CapEx in Q4, as a percent of revenues. We've got some projects coming in which we're finalizing, as well as some new clinical assets. And, we also have quite a few gyms launching in Q3. Hopefully, if they are finalized in time. Just come back for a quick glance at our financial targets through 2025. So it's sort of a short-term target now, really looking forward just over one year. If you look on the left hand side there, you can see that projection we have with the dotted line in terms of the rate of growth. Remember, we didn't start at 1.5 billion in revenues. We started lower than that because part of those revenues was from Covid. Adjusting for that, you can see we are well on track in terms of meeting our target levels. And if you look at our run rate now for this quarter, remember, our revenues are recurring. So if we're showing revenues on there, those revenues are largely recurring. So we're well on track with a 2.1 billion run rate. So, we'll clearly be in excess of €2.2 billion for next year. If we look then in terms of our adjusted EBITDA organic, you can see in that same projection, if you look at the start base, we had to take off the COVID contributions, the profits that we were getting. So our base was much lower. And I think you can see on that with the dotted line as well, that we are well on track in terms of meeting that 350 million organic EBITDA target. We have also included some illustrations here, which remain unchanged with respect to other profit metrics, including leverage. Um, we're now at 3.1, um, our stated level is to be lower than 3.5 or at 3.5. Um. Unless we've got some short-term, larger inorganic activity. But we're well within that measure currently. I hand back to you, Fredrik.

Fredrik Rågmark
29:37 - 32:03

Sure. So, the summary slide. Key takeaways. So, super strong organic growth. Um, very strong cash flow. Joe has talked about that in detail. I commented on that as well, and it was really represented by a superb performance from both Healthcare Services and Diagnostic Services. So we're well on track towards the financial targets Joe just made that point, which will include both increasing revenue, volume, price, and unit volume. It will include continuing to grow our margins for the same reasons that you've heard us repeat for a number of quarters, and the illustrations that we have taken you through in this quarter and this presentation. It will involve generating additional strong cash flow, which will allow us to invest in organic expansion and reduce debt on the balance sheet, and then very likely distribute some money to shareholders over time. So I think we're in a very good position. And I think that's the sort of summary of the quarter. And I would like to sum up also by saying a point I made initially that, you know, this is the last quarter when you have the pleasure to listen to Mr. Ryan as our CFO. And I thought it would be appropriate just to say that I worked out this morning that we have actually delivered 66 quarterly reports together, and 30 of those are in our second iteration as a public company, and 36 of them were in our first iteration as a public company. So 66 quarters, I think, works out to 17.5 years. So, I think you can retire with dignity, Joe. On behalf of the company and all of us, I would like to express a warm thank you for all these years of super strong execution and delivery on the financial front. Thank you, Joe.

Joe Ryan
32:04 - 33:26

Thank you, Frederick. It's been a pleasure to serve as Medicover CFO throughout the entire history of Medicover to date. And I have been very fortunate and lucky. Fredrik, to have such a quality CEO and business partner in creating such a healthcare powerhouse that Medicover is today. It's been a pleasure of a journey. And furthermore, I'd like to thank my colleagues who are with us now, and those who have been part of our journey over the years. As you can imagine, we have had many people coming in and going through their careers with us and leaving as well. They have been on that amazing journey of growth and development. Our history has been challenging at times. We've had lots of memorable times, events, and achievements, but I'd just like to echo what you see in our presentations. And we talk about that in our annual report, which states, 'Caring for your health is all we do,' and that's all we're going to continue to do in more locations with more patients and more people as we grow for many, many years to come. So it was a pleasure and a real honor to be able to serve as the CFO for Medicover. Thank you. Fredrik Rågmark. Sure.

Fredrik Rågmark
33:26 - 33:37

Good. Thank you, Joe. And very nice words. We bring those with us. So with that, I hand over to see if we have any questions to answer from the audience.

Operator
33:42 - 34:01

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Rikard Kranz from Handelsbanken. Please go ahead.

Rikard Kranz
34:04 - 34:30

Good morning and thank you for taking my questions. So starting off, could you remind us of the share of the total installed bed capacity of the six units you mentioned earlier in the presentation? And what are your internal expectations of when the six units could reach, you know, EBIT, adjusted EBITDA to break even as a group to start with. I'll start there. Thank you.

Fredrik Rågmark
34:33 - 35:47

Well, Richard, as you know, we do not record the specific quarters when these startup units are expected to become profitable. The reason I mentioned this quarter is that out of the six units that started in the past two years, two of them actually turned positive in the quarter. So that is then within two years of starting up, which is, I think, really good. I believe if you wish to adopt a more conservative approach, you can anticipate that within three years from India, this outcome would be expected. Now it happened for two of them within two years, which I think is good. Now, the two units that just started in this third quarter are large. So they are significant units that are sort of 300 beds plus, I think, or maybe 250 or 300, both of them. So significant units; I think, as you know, the six combined would be plus or minus 1000 beds. So I think the total capacity currently in India would be somewhere between, I think, 5,000 to 6,000. So, give or take, about 20 percent of installed capacity would be from the past two years. To give you a sense of the magnitude.

Rikard Kranz
35:50 - 36:13

That's helpful. Thank you. And, you know, an impressive growth rate continues in Poland. It would be interesting to hear a little bit of an update on how you expect the quite strong budget uplift for next year, as well as EU funds, to play out from a Medicover perspective in 2025 and 2026. Any incremental updates there?

Fredrik Rågmark
36:14 - 37:54

Well, I mean, we've made the point many times, the question arises often about whether we think the Polish economy will start to impact us more negatively. And I think, as a company, we have weathered the years behind us. I think we have performed very well. If you look at our reported results out of Poland, if anything, Europe, and certainly Poland, is moving into more positive territory from an economic perspective. You take a three-year perspective going forward. And certainly, in Poland, you have what you were addressing here. You have significant amounts of these sorts of EU transfers coming in and improving the economy. So, short term, we're reporting quite solid member growth numbers. The employment market in Poland is somewhat mixed, I would say. So on the one hand, it's quite difficult to find people if you want to hire, but then you've had quite high minimum wage growth, which we have discussed in our reporting for a couple of quarters, and that is sort of impacting quite a bit the employers' willingness to bring on additional people. So, short term, you have a scenario which I wouldn't call soft, but you could describe it as a somewhat mixed employment picture in Poland. But if you take a 12, 18, or 24-month perspective on economic growth and the strength of the economy, I think it offers a really solid outlook. So I think we're in a sort of good position from that perspective.

Rikard Kranz
37:58 - 38:30

Thank you. And a final question on the German lab and diagnostic reimbursement topic. It seems that your view on the impact and outlook has become a bit worse compared to expectations in Q2. Maybe you could help us quantify the impact you're expecting at this point, at least in 2025. Just trying to get a sense of how we should think about the impact throughout the P&L, you know, to get a sense of the magnitude. So, we don't get lost in expectation there. Thank you.

Fredrik Rågmark
38:31 - 39:47

I think you know the right way to answer that question, Richard, is that, you know, if we try to describe that reform to you, it would just get too complicated. So I think the important message to send, based on the point I made before, is that we are addressing some of our cost structure elements and some, as you know, call it revenue sources to mitigate the impact of that reform in '25. So although on the face of it, if you just sat and did nothing, it would have a negative impact on us, which I'm not going to try and quantify. More importantly, we're confident that with the work we do, we will mitigate on a like-for-like basis any impact from that reform on our German operations. And that's why I made the point that, you know, throughout the past two years, with a stable pricing situation and quite an inflationary environment. From a cost perspective, we have, despite that, quite significantly grown our margin out of Germany, which is why we have, I think, a high degree of confidence that we're able to mitigate this going forward.

Joe Ryan
39:48 - 40:16

I think it's worth observing, Fredrik. This is going to cause disruption in the German laboratory sector as well. That may well open up some opportunities. Every cloud has its silver lining, but we don't see that this is going to have a material impact in any way. In terms of our figures for 2025, we will manage through this as we do with other challenges that we manage on a regular basis.

Fredrik Rågmark
40:18 - 40:20

Yeah, that's a good point.

Rikard Kranz
40:20 - 40:22

Very clear. Thank you for taking my questions.

Operator
40:25 - 40:30

The next question comes from Matthias Waddesdon from SEB. Please go ahead.

Unknown 5
40:32 - 40:33

Hello.

Unknown 6
40:33 - 41:16

Good morning. I have three questions today. So first one would be on India; I think previously during the year, you talked about some one-offs here. It has been the divestiture of some smaller hospital units and IVF clinics. And you have had a revamp of a larger unit into an oncology facility, if I'm not mistaken. So maybe if you could talk a little bit about how much this is still affecting you year over year, and when all of those factors are no longer disturbing the picture year on year, and also maybe comment a little bit on whether you're pleased with the initial ramp up in the new units in India. That’s the first one.

Joe Ryan
41:19 - 41:31

Just, just. Could you just repeat that in terms of your question about margins, what it would look like excluding the startup units or when they mature, something like that.

Unknown 6
41:32 - 42:01

No, this is not on the margin side. So it's on the growth rate year on year. Previously, you had some impact from a revamp of a larger unit in India, and you've also had some divestitures in the country that have impacted growth year on year. So when do you expect this to no longer affect you year on year? And then also the initial ramp up of the new units, if you're pleased with what you see, that's the question.

Unknown 7
42:02 - 42:04

Yes, I believe so.

Joe Ryan
42:04 - 44:23

What Fredrik was saying earlier on, which is we're very pleased with the ramp up in terms of the new units. I think we will. We will get to a stage where we have very good occupancy and not too far in the future in our units in Navi Mumbai. It's a fantastic location, and Mumbai's growth continues. We also have to note that it takes some time in the process of getting insurance enrollments, which allows us to address certain market segments. We are well past those initial stages in those units as well. So that then boosts the, um, the sort of more value-added part of the segment of the market as well that we can address. So, we're well on the way in terms of that. And I think that those units in Pune and Navi Mumbai are going to perform exceptionally well. When we look at the new units. They've taken off quite well. The units in Bangalore and Warangal have seen a lot of patients who previously traveled to Hyderabad; I think we're now capturing those patients locally. So that's actually picked up faster than we expected. The development of the unit in Bangalore is progressing according to plan. In terms of the numbers, you see, we are experiencing double-digit growth this quarter. The two units, I believe you are referring to, that we closed and subsequently disposed of, were very small units. So they don't really disrupt anything in terms of development. It's a mixture of those new units with the new growth coming through. And then it's about getting additional occupancy into the older units, and we see a mixed bag in terms of the older ones. Some of our developments are going very well, while others are a bit stalled. So we need to go back and examine how we have the doctors working in some of those. But I think overall, as you can see here in the figures, our growth is evident. And then I think we're doing fine. We think we can continue to have good growth levels year on year in India.

Unknown 6
44:27 - 44:48

Thanks for that. The next one would be: we continue to be, I think, at least impressed by the price increases as you press through. Despite these growing volumes the way you do. So maybe just a little bit of comments on how you see the pricing strategy going into 2025.

Fredrik Rågmark
44:49 - 45:06

Yeah. So, you know, you will see quite a significant price component of growth in 2025 as well. Uh, it will come down relative to '24 because of that fact.

Unknown 8
45:07 - 45:07

Uh, you.

Fredrik Rågmark
45:07 - 45:38

Inflation is coming down in our markets as well. And hence the knock-on price indexation or ability to grow price will correspondingly reduce, but it will be at significantly more elevated levels than it was before all of this began. So relatively speaking, you know, price growth is coming down vis-à-vis 2024, but still on historically much higher levels. I think that's the way to describe it, Mathias.

Unknown 6
45:41 - 46:23

I think that's perfectly clear. And then, I also have a follow-up on Germany. I would tweak that question a little bit. So in terms of the outlook there, do you see these strong volumes coming up to a better level because they are growing quite substantially in Germany, due to competition tailing off from the initial burst of reimbursement levels in that country? And also, if you could just give a sense—I mean, you don't have to be specific—but just a sense on the, let's say, margin development for Germany. Yeah. In 2022, 2023, and maybe year to date this year. That's the third and last one for me.

Fredrik Rågmark
46:25 - 48:31

Yeah. I mean, if I start from the backend of that, I'm not going to be specific for obvious reasons, because we don’t separate our country margins, as you know. But you know, the point I made before Matthias, I think it is, given that Germany is so significant, you're not going to be terribly wrong if you take half of the divisional profit improvement, and perhaps slightly more is represented by Germany being half of the business. And if you work that backwards, you're going to see that there is a significant margin improvement in the German component of what we do, which is really good and very important. And again, I repeat the point I made to Richard previously. Remember, that's in an environment where we had cost inflation significantly above any price compensation. So, that's a significant point to make. Now, why do we see such good volume growth in Germany? I wouldn't attribute it yet to competitive reasons. I think the point you made here that depending on how this sort of pricing thing plays out in 2025, that may work to some people's advantage, perhaps even ours. Time will tell. I don't think that is something we've seen yet. So I think what has driven our volume development in Germany is just a sort of good offer. I mean, some of our specialized testing that we have discussed before is growing very strongly. You know, in specialized immunology or genetics businesses, there is significant double-digit growth. So, the growth is driven by the composition of our test mix, which is expanding very differently across Germany.

Unknown 6
48:34 - 48:36

Okay. Perfect. Thank you so much.

Operator
48:39 - 48:45

The next question comes from Christopher Liljeberg from Carnegie Investment Bank. Please go ahead.

Unknown 6
48:48 - 49:09

Yeah. Thank you. First, I just want to thank you, Joe. Uh, I think I can honestly say that I've never come across a CFO who knows so many details about the business. And, I mean, not only the financial stuff, but also other issues such as, for example, ICU layouts in the Indian hospitals.

Fredrik Rågmark
49:09 - 49:11

So it's been very nice.

Unknown 6
49:11 - 49:13

Working with you these past years.

Unknown 5
49:13 - 49:13

Years.

Joe Ryan
49:14 - 49:15

Thank you, Christopher.

Unknown 6
49:15 - 49:32

And then, to my questions here, coming back to Germany. Um, I think it is fair to say that the situation you expect next year in Germany is not going to be worse than what you have seen in the last two years?

Fredrik Rågmark
49:33 - 49:45

Yeah, that's nice for us, Christopher, I would answer. Yes. So, I think the answer is, shortly, yes. Yes. On that question relating to medical issues.

Unknown 6
49:46 - 50:00

Yes. So, the cost savings and other issues or adjustments you're making are not just to keep margins flat. We could expect that you will be able to continue to improve margins in Germany.

Fredrik Rågmark
50:01 - 50:02

Yes. Correct.

Joe Ryan
50:06 - 50:21

Christopher. That sort of support is grounded in the fact that it affects the whole industry. So the whole industry is going to be moving in certain directions. Um, so we see that it could be positive in some aspects. Minor.

Unknown 5
50:22 - 50:24

Yes. Okay. Yes. Yes.

Unknown 6
50:24 - 50:40

Then on the €5 million negative impact from the new hospitals, I think you referred to the EBITDA level here, but would it be that you are charging those hospitals?

Fredrik Rågmark
50:40 - 50:41

With full.

Unknown 6
50:41 - 50:46

Depositions, i.e. Is the impact as significant further down in the P&L?

Joe Ryan
50:47 - 50:53

Yes, absolutely. Full depreciation is charged on those. Yeah.

Fredrik Rågmark
50:53 - 50:57

It's a beta, not a beta L. It's a beta level.

Unknown 6
50:59 - 51:07

Yes, indeed. So even on a pre-tax profit level, we're talking about 20 million here on an annualized basis.

Unknown 7
51:08 - 51:12

Yeah. It's significant.

Joe Ryan
51:12 - 51:20

In terms of the fall-through to the profit and loss account, which is what we've talked about sequentially now for many years. Yeah.

Unknown 6
51:20 - 51:33

I just wanted to make sure. Yeah, that's good. And then the final question, regarding new upcoming large openings here for the coming quarters and into 2025.

Fredrik Rågmark
51:34 - 52:12

We stand by what we have said before. There's nothing new in addition to that, Christopher. So, you know, we said there are two new openings coming in India and both of them in the Hyderabad area during 2025. And if anything, you know, they think we've said last time we talked about this, it's going to be in the second quarter, and it may be that one of them is going to be a bit later during the year, but there's nothing more beyond what we have said previously that is on the horizon.

Unknown 6
52:14 - 52:36

And when it comes to the competitive situation in India, there have been some M&A deals, etc. But do you see this changing significantly in any other way, or is it just more of the same, that there is a tough competition for resources and a lot of capacity being opened?

Joe Ryan
52:38 - 53:30

Um, Christopher. Um, competition is quite local in the inpatient services, as you can imagine, for obvious reasons. So, our competitors don't stand still. And just the same way, we don't stand still. So we're always facing those challenges. And you see some hospital units changing hands and ownership. And you might get someone who's a little bit more competent at running it, so the competition goes up, but that's just within the mix. Um, nothing unusual in that respect. Um, in the competitive dynamics, what we see with the M&A activity of our competitors is that there is very little new investment in new locations. And that's what we're doing differently; we're establishing new locations. So, the dynamics don't change that much actually on the ground in the local area.

Unknown 5
53:34 - 53:34

Okay.

Unknown 6
53:35 - 53:37

That's interesting. Thank you.

Operator
53:41 - 53:47

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad.

Unknown 9
53:51 - 53:53

We have a few online questions.

Operator
53:53 - 54:02

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Fredrik Rågmark
54:03 - 55:54

I think there's one written question which has not been addressed, which is: can you provide the mix between advanced and standard testing in terms of volume and revenue? And I think we report on that pretty much annually in the annual report. Yeah. So just for reference for the audience, what we define as an advanced diagnostic test in the Diagnostic Services division is where the end customer pays more than €15 for a test. So that is not a scientific definition, but a commercial one. It's a commercial definition. I think the overall price per test in the portfolio is somewhere around €4 or so. So, and I think the average price per test within the advanced diagnostic category is around 35 euros or so. So you see, there's a big difference price-wise between the advanced diagnostic testing and the overall routine testing. And I think the last number we reported, if my memory serves me correctly, was approximately 40, 42, 43% of revenue, and 4 or 5% of test volume. Test volume-wise, a very small proportion of the diagnostic division, but revenue-wise, a very significant element. Importantly, that component is growing faster than the overall total. So, it's an important piece of our strategy. Otherwise, there are no questions that we have not answered, I believe, in terms of the commentary. So with that, I would like to thank you for attending today's call and goodbye.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…